week 8-14 Feb:
• Dr. Reddy’s Laboratories’ U.S. subsidiary Promius Pharma LLC has received U.S. Food and Drug Administration approval for Sernivo (betamethasone dipropionate) spray (0.05%), a product used in the treatment of psoriasis.
• The commercial launch of the product is planned for the coming quarter.
• Sernivo spray is a prescription topical steroid indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.
• Promius, conducted “two successful multi-centre, randomized, double-blind, vehicle-controlled clinical trials in subjects aged 18 years and older with moderate plaque psoriasis to evaluate the safety and efficacy of Sernivo spray.